Jeffrey A. Engelman
877 works · 85,259 citations · h-index 132
Top works
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- Targeting PI3K signalling in cancer: opportunities, challenges and limitations
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- Caveolins, Liquid-Ordered Domains, and Signal Transduction
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib